NVO ▼ -0.3% - Novo Nordisk A/S $NVO is open to considering a direct NYSE listing, replacing the ADR structure U.S. investors use today. CEO told the FT a direct listing could help raise Novo’s U.S. profile, where it generates more than half its revenue. The idea is not currently under active discussion Novo Nordisk shares declined 0.3% following CEO comments to the Financial Times that the company is open to exploring a direct NYSE listing to replace its current American Depositary Receipt structure. The CEO indicated such a move could elevate the company's profile in the U.S., where it generates over half its revenue, though he clarified the idea is not presently under active consideration. The modest decline suggests investors may have mild uncertainty about potential structural changes, despite the company framing a direct listing as strategically advantageous. 23-SEP-2026 06:39 AM ET